The T cell-mediated tumor killing patterns revealed tumor heterogeneous and proposed treatment recommendation in ovary cancer.

IF 2.8 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Xinglin Wen, Beining Yin, Li Lin, Long Liu, Siyuan Weng, Hui Xu, Yuyuan Zhang, Jinhai Deng, Ruiying Liao, Cungeng Fan
{"title":"The T cell-mediated tumor killing patterns revealed tumor heterogeneous and proposed treatment recommendation in ovary cancer.","authors":"Xinglin Wen, Beining Yin, Li Lin, Long Liu, Siyuan Weng, Hui Xu, Yuyuan Zhang, Jinhai Deng, Ruiying Liao, Cungeng Fan","doi":"10.1007/s12672-024-01635-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment, but the role of genes related to T cell-mediated tumor killing (TTK) sensitivity in ovarian cancer (OV) is unclear.</p><p><strong>Methods: </strong>This study analyzed 1367 OV patients and 11 independent cohorts. The unsupervised clustering was conducted to identify three tumor subtypes based on genes that regulate tumor cell sensitivity to TTK (GSTTKs). The biological characteristics, genetic variations, immunological landscape, and therapeutic evaluation for each subtype were further explored.</p><p><strong>Results: </strong>Patients were divided into three reproducible subtypes based on 61 GSTKKs associated with prognosis. C1 was likely to be an invasive subtype with the worst prognosis and highly unstable genome. C2 might be an immune-active subtype with the best prognosis, high immune infiltration and preferable response to immunotherapy. C3 might be a metabolic subtype, resistant to immunotherapy, but sensitive to drug therapy. Following an extensive exploration into a variety of distinct molecular features between the three subtypes, the results suggested that C2 patients were considered to derive significant efficacy from immunotherapy. For C1 and C3 patients, chemotherapy might be an ideal treatment strategy.</p><p><strong>Conclusions: </strong>In this study, three GSTKKs-based subtypes were identified by assessing TTK patterns in OV. These new insights further improved our understanding of GSTTKs and might refine clinical treatment strategies for OV patients.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"753"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621272/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-024-01635-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment, but the role of genes related to T cell-mediated tumor killing (TTK) sensitivity in ovarian cancer (OV) is unclear.

Methods: This study analyzed 1367 OV patients and 11 independent cohorts. The unsupervised clustering was conducted to identify three tumor subtypes based on genes that regulate tumor cell sensitivity to TTK (GSTTKs). The biological characteristics, genetic variations, immunological landscape, and therapeutic evaluation for each subtype were further explored.

Results: Patients were divided into three reproducible subtypes based on 61 GSTKKs associated with prognosis. C1 was likely to be an invasive subtype with the worst prognosis and highly unstable genome. C2 might be an immune-active subtype with the best prognosis, high immune infiltration and preferable response to immunotherapy. C3 might be a metabolic subtype, resistant to immunotherapy, but sensitive to drug therapy. Following an extensive exploration into a variety of distinct molecular features between the three subtypes, the results suggested that C2 patients were considered to derive significant efficacy from immunotherapy. For C1 and C3 patients, chemotherapy might be an ideal treatment strategy.

Conclusions: In this study, three GSTKKs-based subtypes were identified by assessing TTK patterns in OV. These new insights further improved our understanding of GSTTKs and might refine clinical treatment strategies for OV patients.

T细胞介导的肿瘤杀伤模式揭示了卵巢癌的肿瘤异质性并提出了治疗建议。
背景:免疫检查点抑制剂(ICIs)极大地改善了癌症治疗,但与T细胞介导的肿瘤杀伤(TTK)敏感性相关的基因在卵巢癌(OV)中的作用尚不清楚。方法:本研究分析了1367例OV患者和11个独立队列。基于调节肿瘤细胞对TTK敏感性的基因(GSTTKs),进行无监督聚类来鉴定三种肿瘤亚型。进一步探讨各亚型的生物学特性、遗传变异、免疫学景观和治疗评价。结果:基于61个与预后相关的GSTKKs,将患者分为3个可重复的亚型。C1可能是一种侵袭性亚型,预后最差,基因组高度不稳定。C2可能是一种免疫活性亚型,预后最好,免疫浸润高,免疫治疗反应较好。C3可能是代谢亚型,对免疫治疗有抗性,但对药物治疗敏感。在对三种亚型之间的各种不同分子特征进行了广泛的探索之后,结果表明C2患者可以从免疫治疗中获得显着的疗效。对于C1和C3患者,化疗可能是一种理想的治疗策略。结论:在本研究中,通过评估OV中的TTK模式,确定了三种基于gstkks的亚型。这些新发现进一步提高了我们对GSTTKs的理解,并可能完善OV患者的临床治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Discover. Oncology
Discover. Oncology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.40
自引率
9.10%
发文量
122
审稿时长
5 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信